257 related articles for article (PubMed ID: 36013202)
1. The Role of Angiotensin Receptor Blockers in the Personalized Management of Diabetic Neuropathy.
Kostourou DT; Milonas D; Polychronopoulos G; Sofogianni A; Tziomalos K
J Pers Med; 2022 Jul; 12(8):. PubMed ID: 36013202
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic management of diabetic nephropathy.
Vivian EM; Rubinstein GB
Clin Ther; 2002 Nov; 24(11):1741-56; discussion 1719. PubMed ID: 12501871
[TBL] [Abstract][Full Text] [Related]
3. A systematic review of the role of renin angiotensin aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathy.
Rahimi Z; Moradi M; Nasri H
J Res Med Sci; 2014 Nov; 19(11):1090-8. PubMed ID: 25657757
[TBL] [Abstract][Full Text] [Related]
4. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
Pathak JV; Dass EE
Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
[TBL] [Abstract][Full Text] [Related]
5. EVALUATING THE PRESCRIPTION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR RECEPTOR BLOCKERS IN PATIENTS WITH DIABETES IN JORDAN.
Mayyas F; Bataineh W; Jarab A
Endocr Pract; 2017 Nov; 23(11):1289-1296. PubMed ID: 28816537
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
Hughes DB; Britton ML
Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
[TBL] [Abstract][Full Text] [Related]
7. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
[TBL] [Abstract][Full Text] [Related]
8. Blood pressure lowering for the prevention and treatment of diabetic kidney disease.
Thomas MC; Atkins RC
Drugs; 2006; 66(17):2213-34. PubMed ID: 17137404
[TBL] [Abstract][Full Text] [Related]
9. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers: New-onset diabetes mellitus stratified by statin use.
Shin J; Kim H; Yim HW; Kim JH; Lee S; Kim HS
J Clin Pharm Ther; 2022 Jan; 47(1):97-103. PubMed ID: 34668200
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
Crook ED; Preddie DC
Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
[TBL] [Abstract][Full Text] [Related]
12. [The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus].
Ravera M; Deferrari L; Ratto E; Vettoretti S; Parodi D; Deferrari G
Ital Heart J Suppl; 2003 Mar; 4(3):210-6. PubMed ID: 12784755
[TBL] [Abstract][Full Text] [Related]
13. Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.
Powers B; Greene L; Balfe LM
J Manag Care Pharm; 2011 Oct; 17(8 Suppl):S1-14. PubMed ID: 22088101
[TBL] [Abstract][Full Text] [Related]
14. Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis.
Wang B; Wang F; Zhang Y; Zhao SH; Zhao WJ; Yan SL; Wang YG
Lancet Diabetes Endocrinol; 2015 Apr; 3(4):263-74. PubMed ID: 25660574
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
Kuan YC; Huang KW; Yen DJ; Hu CJ; Lin CL; Kao CH
Int J Cardiol; 2016 Oct; 220():462-6. PubMed ID: 27390970
[TBL] [Abstract][Full Text] [Related]
16. The potential role of angiotensin converting enzyme and vasopeptidase inhibitors in the treatment of diabetic neuropathy.
Yorek MA
Curr Drug Targets; 2008 Jan; 9(1):77-84. PubMed ID: 18220715
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
Israili ZH
J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
[TBL] [Abstract][Full Text] [Related]
18. ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure - A network meta-analysis.
Ricci F; Di Castelnuovo A; Savarese G; Perrone Filardi P; De Caterina R
Int J Cardiol; 2016 Aug; 217():128-34. PubMed ID: 27179902
[TBL] [Abstract][Full Text] [Related]
19. [Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in metabolic disorders: hypercholesterolaemia and diabetes].
Strawn WB
Drugs; 2002; 62 Spec No 1():31-41. PubMed ID: 12036387
[TBL] [Abstract][Full Text] [Related]
20. Prevention of the complications of diabetes.
Vinik AI; Vinik E
Am J Manag Care; 2003 Mar; 9(3 Suppl):S63-80; quiz S81-4. PubMed ID: 12653455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
